Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oneness Biotech CoLUX:ONEA 59 PS Ratio is 548.84 as of Jul. 17, 2026, which is 27% below its 10-year median of 755.34. GuruFocus rates LUX:ONEA with a GF Score™ of 59/100 and a GF Value™ of $35.65. The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Oneness Biotech Co ranks worse than 89.14% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Oneness Biotech Co's share price is $23.60.
Oneness Biotech Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04. Hence, Oneness Biotech Co's PS Ratio for today is 548.84.
The historical rank and industry rank for Oneness Biotech Co's PS Ratio or its related term are showing as below:
LUX:ONEA'
s PS Ratio Range Over the Past 10 Years
Min: 60.29 Med: 755.34 Max: 5506.29
Current: 200.74
During the past 13 years, Oneness Biotech Co's highest PS Ratio was 5506.29. The lowest was 60.29. And the median was 755.34.
LUX:ONEA's PS Ratio is ranked worse than 89.14% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs LUX:ONEA: 200.74
Oneness Biotech Co Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Oneness Biotech Co was 8.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -50.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 38.50% per year.
During the past 13 years, Oneness Biotech Co's highest 3-Year average Revenue per Share Growth Rate was 268.90% per year. The lowest was -59.10% per year. And the median was 20.65% per year.
Back to Basics: PS Ratio
Oneness Biotech Co (LUX:ONEA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Oneness Biotech Co PS Ratio Related Terms
Oneness Biotech Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oneness Biotech Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Oneness Biotech Co's Share Price of today is $23.60. Oneness Biotech Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Oneness Biotech Co (LUX:ONEA) has a PS Ratio of 548.84 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oneness Biotech Co and its competitors. This is 27% below median its historical median of 755.34. Over the past decade, Oneness Biotech Co's PS Ratio has ranged from 60.29 to 5,506.29. According to the industry distribution chart, Oneness Biotech Co ranks #829 out of 930 companies in the Biotechnology industry, placing it in the top 89.1%.
Is Oneness Biotech Co's PS Ratio too high?
Oneness Biotech Co's current PS Ratio of 548.84 is 27% below median its 10-year median of 755.34. Over the past 10 years, this metric has ranged from a low of 60.29 to a high of 5,506.29. The Biotechnology industry median PS Ratio is 9.30. Oneness Biotech Co's value of 548.84 is 5801.5% above this industry median. Based on the distribution chart, Oneness Biotech Co ranks #829 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #829 out of 930 companies for PS Ratio. This places Oneness Biotech Co in the lower half of its industry. The industry median PS Ratio is 9.30. Oneness Biotech Co's value of 548.84 is 5801.5% above this benchmark. Historically, Oneness Biotech Co's own PS Ratio has ranged from 60.29 to 5,506.29 over the past decade. While the company's 10-year median is 755.34 vs. the industry median of 9.30, Oneness Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current PS Ratio of 548.84 is 5801.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Oneness Biotech Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current PS Ratio is 548.84, which is 27% below median its own 10-year median of 755.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current PS Ratio of 548.84. The stock's GF Value™ is $35.65, compared to a current price of $23.60 — trading 33.8% below its estimated fair value. The current PS Ratio is 548.84, which is 27% below median its 10-year median of 755.34 and 5801.5% above the Biotechnology industry median of 9.30. Oneness Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current PS Ratio is 548.84 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 33.8% below its estimated GF Value™ of $35.65.
Key valuation signals for LUX:ONEA:
PS Ratio: 548.84 (27% below median its 10-year median of 755.34)
GF Value™: $35.65 vs. price of $23.60 (33.8% below fair value)
Industry Position: 5801.5% above the Biotechnology median (#829 of 930)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score
Get the complete analysis for LUX:ONEA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
